Key Highlights

  • Shares are trading up 7.17% at $29.21 versus a prior close of $27.25.
  • Management will present at Guggenheim, Jefferies and Evercore ISI events in November.
  • A Phase 3 desmoid tumor trial is expected to start in the first half of 2027.

Parabilis Medicines (NASDAQ:PBLS) shares are trading up 7.17% at $29.21 today after the company announced its November investor conference schedule, giving investors upcoming catalysts for updates on lead program zolucatetide. The stock bounced after closing down about 3.8% in the prior session, though it remains below its 50-day average near $32.7 and within a 52-week range of $20.00 to $42.49.

Parabilis Medicines, formerly Fog Pharmaceuticals and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company that uses its proprietary, AI- and physics-enabled Helicon platform to engineer stabilized, cell-penetrant helical peptides targeting historically undruggable intracellular proteins, mainly in oncology. It has about 145 employees and went public in June 2026.

Three Conferences Between November 9 and December 2

Chairman and Chief Executive Mathai Mammen and other members of management will take part in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on November 9, a company presentation at the Jefferies Global Healthcare Conference in London on November 16, and a fireside chat at the Evercore ISI 9th Annual Healthcare Conference in Miami on November 30.

Live webcasts will be available in the investors section of the company's website, with replays following. Analyst sentiment is constructive, with a consensus target near $41, and biotech was broadly firm, with the XBI up roughly 2% in a mixed market.

Zolucatetide Targets the Wnt Pathway Across Several Tumor Types

The lead investigational medicine, zolucatetide, is the first direct inhibitor of the beta-catenin:TCF interaction, a central node in the Wnt/beta-catenin pathway. It is being evaluated in desmoid tumors, familial adenomatous polyposis, adamantinomatous craniopharyngioma, hepatocellular carcinoma and other solid tumors.

A global Phase 3 trial in desmoid tumors is expected to start in the first half of 2027. Beyond zolucatetide, Parabilis is pursuing a follow-on beta-catenin degrader and Helicon-based programs against ERG and allosteric AR in prostate cancer. The company has no approved products or Revenue and is funded by a roughly $770 million upsized IPO plus a Regeneron collaboration that included a $50 million upfront payment.

Fireside Chats Offer the Next Look at the Phase 3 Plan

With no data readout scheduled in the release, the conference appearances are the main opportunity for management to discuss clinical timing. The shares remain well below their 52-week high of $42.49.